A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)— ...

New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures New data sought to evaluate the MiniMed™ 780G ...

Medtronic Diabetes has expanded U.S. pharmacy formulary access for its MiniMed 780F insulin pump through agreements with ...

The first study by Dr. Goran Petrovski, MD, PhD, of Sidra Medicine, randomly assigned adolescents using the MiniMed™ 780G system (n=34) into two groups, with some entering a fixed pre-set number of ...

A real-world retrospective analysis published in Diabetes Care found that Medtronic’s MiniMed 780G insulin system users met American Diabetes Association time-in-range goals even on days when mealtime ...

Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...

Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode DUBLIN, June 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today ...

GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones ...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the ...